Lifevantage (LFVN) Competitors

Arbutus Biopharma (NASDAQ:ABUS) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Is ABUS or LFVN more profitable?

Lifevantage has a net margin of 4.12% compared to Arbutus Biopharma's net margin of -352.24%. Lifevantage's return on equity of 34.67% beat Arbutus Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	-352.24%	-59.28%	-44.11%
Lifevantage	4.12%	34.67%	15.24%

Does the media prefer ABUS or LFVN?

In the previous week, Arbutus Biopharma had 3 more articles in the media than Lifevantage. MarketBeat recorded 6 mentions for Arbutus Biopharma and 3 mentions for Lifevantage. Lifevantage's average media sentiment score of 1.78 beat Arbutus Biopharma's score of 0.43 indicating that Lifevantage is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Lifevantage	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has better valuation and earnings, ABUS or LFVN?

Lifevantage has higher revenue and earnings than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$6.17M	104.70	-$69.92M	-$0.29	-11.62
Lifevantage	$200.16M	0.86	$2.94M	$0.69	19.83

Do analysts prefer ABUS or LFVN?

Arbutus Biopharma currently has a consensus price target of $5.50, suggesting a potential upside of 63.20%. Lifevantage has a consensus price target of $30.50, suggesting a potential upside of 122.95%. Given Lifevantage's higher possible upside, analysts clearly believe Lifevantage is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Lifevantage	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk and volatility, ABUS or LFVN?

Arbutus Biopharma has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Lifevantage has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500.

Do institutionals & insiders hold more shares of ABUS or LFVN?

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 35.3% of Lifevantage shares are held by institutional investors. 20.3% of Arbutus Biopharma shares are held by insiders. Comparatively, 20.7% of Lifevantage shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Lifevantage beats Arbutus Biopharma on 10 of the 15 factors compared between the two stocks.